Relmada Therapeutics, Inc. (RLMD)
NASDAQ: RLMD · Real-Time Price · USD
0.6467
-0.0185 (-2.78%)
At close: Jul 25, 2025, 4:00 PM
0.6630
+0.0163 (2.52%)
After-hours: Jul 25, 2025, 7:42 PM EDT
Relmada Therapeutics Employees
Relmada Therapeutics had 17 employees as of December 31, 2024. The number of employees decreased by 3 or -15.00% compared to the previous year.
Employees
17
Change (1Y)
-3
Growth (1Y)
-15.00%
Revenue / Employee
n/a
Profits / Employee
-$4,453,570
Market Cap
21.47M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 17 | -3 | -15.00% |
| Dec 31, 2023 | 20 | 6 | 42.86% |
| Dec 31, 2022 | 14 | 4 | 40.00% |
| Dec 31, 2021 | 10 | -4 | -28.57% |
| Dec 31, 2020 | 14 | 8 | 133.33% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
RLMD News
- 11 days ago - Relmada Therapeutics Appoints Renowned Urologic Oncologist, Yair Lotan, MD, to Chair the Clinical Advisory Board and Support Development of NDV-01 - GlobeNewsWire
- 17 days ago - DIMERx Appoints Biotech Leader Sergio Traversa, PharmD, to Board of Directors - GlobeNewsWire
- 5 weeks ago - Relmada Therapeutics Appoints Urology Expert Raj S. Pruthi, MD as CMO-Urology - GlobeNewsWire
- 2 months ago - Relmada Therapeutics, Inc. (RLMD) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Relmada Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 2 months ago - Relmada Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025 - GlobeNewsWire
- 3 months ago - Relmada Therapeutics Presents Positive Initial Phase 2 NDV-01 Data at AUA2025 - GlobeNewsWire
- 3 months ago - UPDATE -- Relmada Therapeutics To Present NDV-01 Data at AUA2025 - GlobeNewsWire